For system help please email Penn’s iLab support at: iLab.Support@pennmedicine.upenn.edu
(hide this warning on this page)
The CRISPR-Cas9 mouse targeting core at the Perelman School of Medicine, University of Pennsylvania, has been operational since February 2017. Jorge HENAO-MEJIA has served as Scientific Director and Leonel JOANNAS as the Technical Director. The core is in the Institute for Immunology (IFI) and the Scientific and Technical Directors are part of the IFI. In addition, this recently established core is composed of one research technologist “A” who works under our guidance. The mission of the CRISPR-Cas9 targeting core is to streamline procedures to facilitate the use of the CRISPR/Cas9 genome editing technology by the larger UPenn/CHOP community to generate novel mouse genetic tools rapidly and economically. This core has had a significant positive impact on the community. Researchers who work with mice and rats to model human diseases have enthusiastically taken up these tools. Projects that may have taken years using older techniques, such as examining the effects of disrupting several genes at once, generating point mutations, or inserting fluorescent proteins, now take just a couple of months. It is also easier to produce more subtle changes, like tweaking just a few DNA nucleotides in a gene in a way that simulates a variation found in humans. In addition, our R&D efforts in this area should enable UPenn/CHOP to remain at the forefront of this technology.
Our RRID is: RRID:SCR_022378. Please cite us using this identifier when publishing your results!
By using the CRISPR/Cas9 technology, we can now generate pre-clinical mouse and rat models for research purposes in a matter of 3 to 4 weeks. Moreover, it allows us to generate models that more closely mimic human diseases. Hence, this truly has been a revolution in the biomedical research field and its impact is already observed in the clinics. We have already developed more than two hundred different targeting strategies during our first two and a half years of being operational. The CRISPR-Cas9 Mouse Targeting Core at Penn is a state-of-the-art facility that has an outstanding record of accomplishment in the production of genetically altered mice and rats for investigators at Penn and outside institutions, within and the state of Pennsylvania, as well as overseas.
Name | Role | Phone | Location | |
---|---|---|---|---|
Jorge HENAO-MEJIA |
Scientific Director CRISPR/Cas9 Mouse Targeting Facility
|
Only e-mail inquiries!
|
jhena@pennmedicine.upenn.edu
|
BRB II/III, 3rd Floor, Room # 312
|
Leonel D. JOANNAS |
Technical Director CRISPR/Cas9 Mouse Targeting Facility
|
Only e-mail inquiries!
|
ljoannas@pennmedicine.upenn.edu
|
BRB II/III, 3rd Floor, Room # 320
|
https://www.google.com/maps/place/Biomedical+Research+Building+II%2FIII,+421+Curie+Blvd,+Philadelphia,+PA+19104/@39.9478702,-75.1990227,17z/data=!3m1!4b1!4m5!3m4!1s0x89c6c65ec9c3306f:0x810d59d739a86378!8m2!3d39.9478702!4d-75.196834